Gaibazzi Nicola, Ziacchi Vigilio
Cardiology Department, Ospedale Civile di Desenzano del Garda, Desenzano del Garda (BS), Italy.
BMC Cardiovasc Disord. 2004 Mar 23;4:1. doi: 10.1186/1471-2261-4-1.
Normal coronary arteries may coexist with abnormal coronary and systemic endothelial function in patients with chest pain. Recent work by the renowned Pisa echo-group elegantly suggests that isolated ST-segment depression during stress-echo (SE) can be used as a marker of coronary endothelial dysfunction, in the absence of stress-inducible wall motion abnormalities and in the absence of angiographically-significant coronary artery disease (CAD). The long chain n-3 polyunsaturated fatty acids (PUFAs) have been reported to possess several properties that may positively influence vascular function. The present study's hypothesis is that a 4 month-course of oral supplementation with n-3 PUFAs can reverse endothelial dysfunction.
Subjects were selected on the basis of the following criteria: 1) reported chest pain syndrome, 2) significant ST-segment depression during an otherwise normal SE, 3) absence of angiographically-significant CAD. Subjects underwent a 4-month course of oral supplementation with commercially available n-3 PUFA, 1 g once a day. Normalization of endothelial dysfunction was defined, at the end of the supplementation period, by the absence of significant ST-segment depression during repeat SE. We tested the aforementioned hypothesis in a very small series of consecutive subjects, with the intent to produce a hypothesis-generating study.
Seven out of the total nine subjects enrolled (77.8%) had normal ST-segment during repeat SE performed after the 4 month course of therapy.
A striking rate of reversion of SE-induced ST-segment depression after oral n-3 PUFAs suggests reversion of coronary endothelial dysfunction; nonetheless these data need to be validated in larger, placebo-controlled studies.
胸痛患者中,正常冠状动脉可能与异常的冠状动脉及全身内皮功能并存。著名的比萨超声心动图研究团队近期的研究巧妙地表明,在无应激诱导的室壁运动异常且无血管造影显示显著冠状动脉疾病(CAD)的情况下,负荷超声心动图(SE)期间孤立的ST段压低可作为冠状动脉内皮功能障碍的标志物。据报道,长链n-3多不饱和脂肪酸(PUFAs)具有多种可能对血管功能产生积极影响的特性。本研究的假设是,为期4个月的口服n-3 PUFAs补充疗程可逆转内皮功能障碍。
根据以下标准选择受试者:1)有胸痛综合征报告;2)在其他方面正常的SE期间有显著的ST段压低;3)无血管造影显示显著的CAD。受试者接受为期4个月的口服市售n-3 PUFA补充疗程,每天1克。在补充期结束时,通过重复SE期间无显著ST段压低来定义内皮功能障碍的正常化。我们在一小系列连续受试者中检验上述假设,旨在进行一项产生假设的研究。
在总共9名入组受试者中,7名(77.8%)在4个月疗程治疗后的重复SE期间ST段正常。
口服n-3 PUFAs后,SE诱导的ST段压低出现显著的逆转率,提示冠状动脉内皮功能障碍得到逆转;尽管如此,这些数据仍需在更大规模的安慰剂对照研究中得到验证。